Morocco’s Cannabis Industry Expands Rapidly in 2024 Amid Regulatory Changes

Morocco has emerged as one of Africa's most significant cannabis markets, with 2024 marking a pivotal inflection point as regulatory frameworks solidify and commercial cultivation licenses accelerate. The North African nation, already the world's largest cannabis producer by volume (estimated 700+ metric tons annually), is transitioning from an informal, subsistence-based sector into a structured, export-oriented industry—a shift with profound implications for European investors seeking exposure to the global cannabis economy's most regulated, accessible entry point.

The regulatory transformation began in earnest following Morocco's 2018 legalization of medical and industrial cannabis, but 2024 has seen implementation accelerate dramatically. The government has now issued hundreds of cultivation licenses to both domestic operators and international joint ventures, establishing formal supply chains, quality standards, and tax frameworks. This legitimization addresses the primary barrier that deterred European institutional capital previously: legal ambiguity and reputational risk.

For European entrepreneurs, Morocco's cannabis expansion represents a rare African opportunity meeting three critical criteria simultaneously: established infrastructure, European regulatory alignment, and first-mover advantage. The country's proximity to EU markets (Gibraltar Strait crossing time: under 2 hours), existing pharmaceutical and agricultural export ecosystems, and French-speaking governance structures reduce operational friction compared to other African cannabis jurisdictions. Additionally, Morocco's Mediterranean climate produces premium cannabis with CBD/THC profiles competitive with European and North American cultivars—critical for pharmaceutical-grade production targeting EU GMP (Good Manufacturing Practice) certification.

The market opportunity is substantial. Current estimates place Morocco's legal cannabis market at €200–300 million annually, with potential expansion to €2+ billion by 2028 as pharmaceutical partnerships scale and EU medical cannabis approvals increase. The EU market for cannabis-derived pharmaceuticals and medical products is projected to exceed €7 billion by 2027, and Morocco is positioned to capture 15–20% of European supply through cost advantages (cultivation costs 40–60% lower than Spain or Netherlands) and established logistics networks.

However, European investors must navigate three material risks. First, regulatory momentum could reverse if political pressure from conservative constituencies gains ground—Morocco's government remains sensitive to religious and social concerns despite progressive policy shifts. Second, the EU's harmonized cannabis classification remains incomplete; medical approvals remain fragmented by member state, creating demand volatility. Third, the informal sector persists: an estimated 200,000+ family farms operate unlicensed, creating price pressure that could undermine margins for licensed operators if not formalized through buyout programs or cooperative structures.

The most sophisticated European entry strategies involve joint ventures with established Moroccan agricultural firms or partnerships with licensed cultivation operators seeking capital and technical expertise rather than direct ownership. French and Spanish agricultural companies are already structuring deals; German pharmaceutical firms are evaluating supply agreements. Early movers in licensing and partnerships (secured by Q4 2024) are likely to achieve preferential positioning before capital competition intensifies in 2025–2026.